TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Glancy Prongay & Murray Llp
Deadline Alert: Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Cytokinetics faces potential securities fraud lawsuit after disclosing FDA review period extension for cardiac drug aficamten, resulting in stock price decline due to alleged misleading statements about drug submission.

Insights
WFCpD   neutral

Analyst downgraded price target for Everest Group from $383 to $343, maintaining an 'equal weight' recommendation


CYTK   negative

Stock experienced significant price drops after revealing FDA review complications, potential omission of risk mitigation strategy, and potential misleading communications about drug submission process